



Nutrición Hospitalaria

ISSN: 0212-1611

nutricion@grupoaran.com

Sociedad Española de Nutrición
Parenteral y Enteral
España

Penaforte, Fernanda R.O.; Japur, Camila C.; Diez-Garcia, Rosa W.; Chiarello, Paula G.
Effects of a high-fat meal on postprandial incretin responses, appetite scores and ad
libitum energy intake in women with obesity

Nutrición Hospitalaria, vol. 34, núm. 2, marzo-abril, 2017, pp. 376-382

Sociedad Española de Nutrición Parenteral y Enteral
Madrid, España

Available in: <http://www.redalyc.org/articulo.oa?id=309250505019>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org

redalyc.org

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative



Nutrición Hospitalaria



Trabajo Original

Obesidad y síndrome metabólico

Effects of a high-fat meal on postprandial incretin responses, appetite scores and *ad libitum* energy intake in women with obesity

Efectos de una comida rica en grasas en la respuesta posprandial de las incretinas, del apetito y en la ingestión de energía *ad libitum* en mujeres con obesidad

Fernanda R.O. Penaforte^{1,2}, Camila C. Japur^{2,3}, Rosa W. Diez-García^{2,4} and Paula G. Chiarello⁴

¹Institute of Health Sciences. Department of Nutrition. Federal University of "Triângulo Mineiro". Uberaba, Brazil. ²Laboratory of Eating Practices and Behavior (PratiCA). Course of Nutrition and Metabolism. University of São Paulo. Ribeirão Preto, Brazil. ³Course of Nutrition. Federal University of Uberlândia. Uberlândia, Brazil. ⁴Course of Nutrition and Metabolism. Ribeirão Preto. Medical School. University of São Paulo. Ribeirão Preto, Brazil

Abstract

Background: Considering the possible role of triglycerides (TG), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in the regulation of appetite, this study aimed to compare high fat meal-induced response of GIP and GLP-1, appetite scores and *ad libitum* energy intake in women with obesity, according to postprandial increment in triglyceridemia (Δ TG).

Methods: Thirty-three no-diabetic women (BMI = 35.0 ± 3.2 kg.m⁻²) were divided into two groups: Group with Δ TG \leq median were called "Low TG change -LTG" and Δ TG $>$ median, "High TG change - HTG". Plasma concentrations of GIP, GLP-1 and appetite sensations were measured prior to, and every 30 min for 180 min after ingestion of a high-fat breakfast. An *ad libitum* lunch was served 3 h after the test meal.

Results: The AUC incrementalGIP were significant lower in HTG vs. LTG group ($p = 0.03$). The same was observed for GIP levels at 150 min ($p = 0.03$) and at 180 min ($p < 0.01$). Satiety was lower in HTG at 120 min ($p = 0.03$) and 150 min ($p < 0.01$). The AUC totalGLP1 were similar between groups and there were no between-group differences for the GLP-1 at each time point. *Ad libitum* food intake were also similar between groups.

Conclusions: The HTG group exhibited differences in satiety scores and lower postprandial secretion of GIP, however with no impact on *ad libitum* food intake in short term.

Key words:

Incretins. Glucagon-like peptide 1. Glucose-dependent insulinotropic polypeptide. Hunger. Appetite. Food intake.

Resumen

Introducción: teniendo en cuenta las posibles acciones de los triglicéridos (TG), del *glucose-dependent insulinotropic polypeptide* (GIP) y del *glucagon-like peptide-1* (GLP-1), en la regulación del apetito (hambre y saciedad), este estudio tuvo como objetivo comparar la respuesta posprandial inducida por una comida rica en grasas en los niveles del GIP y GLP-1, en el apetito y en la ingestión de energía *ad libitum* en mujeres con obesidad, clasificadas de acuerdo con el aumento de la trigliceridemia postprandial (Δ TG).

Métodos: treinta y tres mujeres sin diabetes (IMC = $35,0 \pm 3,2$ kg.m⁻²) fueron clasificadas en dos grupos: grupo con Δ TG \leq mediana ("bajo cambio en los TG - LTG") y grupo Δ TG $>$ mediana ("alto cambio en los TG-HTG"). Los niveles plasmáticos del GIP, GLP-1 y del apetito fueron evaluados antes y cada 30 minutos durante 180 minutos después de la ingestión de un desayuno rico en grasas. Un almuerzo *ad libitum* fue servido 3 h después del desayuno.

Resultados: el área bajo la curva (AUC) del aumento del GIP (AUC aumentoGIP1) fue significativamente menor en el grupo HTG vs. LTG ($p = 0,03$). Lo mismo se observó para los niveles del GIP en los 150 minutos ($p = 0,03$) y en los 180 minutos ($p < 0,01$). La saciedad fue menor en el grupo HTG en los 120 minutos ($p = 0,03$) y en los 150 minutos ($p < 0,01$). La AUC totalGLP1 fue similar entre los grupos y no hubo diferencias entre ellos para los niveles del GLP-1 en los tiempos evaluados. La ingesta alimentaria *ad libitum* también fue similar entre los grupos.

Conclusiones: el grupo HTG presentó diferencias en la saciedad y menor secreción posprandial del GIP, sin embargo, sin impacto en la ingesta de alimentos *ad libitum* en el corto plazo.

Palabras clave:

Incretinas. Péptido análogo al glucagón tipo 1. Polipéptido insulínotropo dependiente de glucosa. Hambre. Apetito. Ingesta alimentaria.

Received: 15/06/2016

Accepted: 28/07/2016

Funding: This work was supported by FAPESP (Fundação de Amparo a Pesquisa do Estado de São Paulo).

Authorship: Fernanda R.O. Penaforte: Contribution in the collection and interpretation of data, statistical analysis and writing the article. Camila C. Japur: Contribution in the interpretation of data, statistical analysis and writing the article. Rosa WD Garcia: Contribution in the interpretation of data, statistical analysis and writing the article. Paula G. Chiarello: Contribution in the interpretation of data, statistical analysis and writing the article.

Penaforte FRO, Japur CC, Diez-García RW, Chiarello PG. Effects of a high-fat meal on postprandial incretin responses, appetite scores and *ad libitum* energy intake in women with obesity. Nutr Hosp 2017;34:376-382

DOI: <http://dx.doi.org/10.20960/nh.215>

Correspondence:

Fernanda Rodrigues de Oliveira Penaforte. Department of Nutrition. Federal University of "Triângulo Mineiro". Av. Frei Paulino, 30. Bairro Abadia, CEP 38025-180. Uberaba, MG, Brazil
e-mail: fernandaropenaforte@gmail.com

INTRODUCTION

The homeostatic mechanisms regulating food intake rely on a neuroendocrine system that involves peripheral and central signaling. The peripheral gastrointestinal signs consist of a series of peptides that are produced in response to food intake and modulate hunger and satiety (1). There is growing evidence to suggest that glucagon-like peptide-1 (GLP-1) is one of the mediators of the post-meal satiety response. The main mechanism of satiety exerted by GLP-1 is related to the "ileal brake", which slows down gastric emptying (2-4). Previous studies have shown that peripheral GLP-1 infusion increases satiety and reduces hunger in a dose-dependent way (3). The underlying mechanisms of action combine slow gastric emptying with direct effects on central nervous system (2). However, these effects are impaired in the obesity and individuals with obesity exhibit attenuated postprandial GLP-1 secretion in comparison to normal-weight controls, which may harm food intake regulation (5-7).

Importantly, most studies evaluating the role of GLP-1 in hunger and satiety have employed peripheral infusion of this hormone, which elevates the serum GLP-1 levels to supraphysiological values, and in these conditions it increases satiety and reduces hunger and energy intake in the short term (8-10). However, gaps in the knowledge of the role of this hormone in appetite modulation in a physiological way, that is, secondary to food intake, still exist, especially in obesity.

In contrast, whether glucose-dependent insulinotropic polypeptide (GIP) has a role in appetite modulation remains unclear. Raben et al. (1994) (11) showed that a higher postprandial GIP response to a high-fat meal were seen in women after weight loss compared to normal-weight controls, and the authors suggest that GIP may promote hunger and excessive food intake. Other studies have founded that postprandial GIP response was inversely related to the subsequent feeling of satiety (5,12,13). On the other hand, positive (14) or neutral (9,10,15) correlation between postprandial GIP and satiety were also observed.

Added to this, evidences in animal studies suggests the involvement of the TG, which are markedly elevated after a high-fat meal, in stimulate hypothalamic peptides known to increase feeding (16-19), and the hyperphagia after a high-fat meal is preceded by a marked increase in circulating TG levels (19).

In this context, the primary aim of the present study was to compare the response of GLP-1 and GIP and the *ad libitum* energy intake to a standardized high-fat test meal in women with obesity classified according to the change in plasma TG after this meal. We also wanted to examine the relationship between postprandial GLP-1, GIP and TG responses with subjective appetite regulation (hunger and satiety) and *ad libitum* energy intake.

MATERIALS AND METHODS

STUDY DESIGN AND SUBJECTS

This is a transversal clinical study. Thirty three women with obesity (BMI 30.0-39.9 kg.m⁻²) between the ages of 20 and 45

years were recruited by posters in public places, e-mail and radio programs. None of the subjects used oral hypoglycemic agents, contraceptives and/or hormones, or anti-psychotic with drugs (washout of 3 months); had been diagnosed with diabetes mellitus, hypertriglyceridemia, thyroid dysfunction, hormone disorders; infections diseases or eating disorders; did not like the foods used in the study (bread, margarine, cheese, whole milk, pasta, tomato sauce and ground meat); had undergone nutritional monitoring during the previous 3 months; were pregnant or nursing or were in a menopausal period.

To compare the role of change in circulating TG after a high-fat meal in the postprandial response of GLP-1 and GIP and the *ad libitum* energy intake, women were classified in two groups according to their TG response after this meal. The median was used as a cutoff point of the postprandial change in TG levels: ΔTG in % = $(TG \text{ at } 180 \text{ min} - TG \text{ at } 0 \text{ min}) \times 100 / TG \text{ at } 0 \text{ min}$. Group $\Delta TG \leq \text{median}$ were called "Low TG change - LTG" and $\Delta TG > \text{median}$, "High TG change - HTG".

The study was approved by the Research Ethics Committee of University of São Paulo, Ribeirão Preto Medical School (process number 4618/2009). The patients received 2 consent forms for signature, one before and the other after the study. Only after the study the women were informed that *ad libitum* food intake would be quantified, thus preventing them from being influenced by this information regarding the amount of food to be consumed.

HIGH-FAT MEAL

On each test day, patients arrived in the research unit in the morning after a 12 h overnight fast. A standardized, fixed energy high-fat breakfast (50 g of french bread with 15 g of margarine and 20 g of cheese and 150 ml whole milk; energy 414 kcal with 50% calories from fat, 35% from carbohydrates and 15% from protein) was then served, and they were instructed to eat all the food offered. Previous studies with high-fat meals also used this same percentage of energy from fat (20,21). Our aim with the high-fat meal was to elicit a sharp rise in the TG levels and stimulate physiological GIP and GLP-1 secretion (22,23).

AD LIBITUM ENERGY INTAKE

The *ad libitum* meal (lunch) were offered three hours after breakfast and consisted of pasta bolognese. The preparation of the pasta and sauce was standardized and rigorously applied on each day of administration. Each *ad libitum* meal consisted of 1,900 g (energy density 1.22 kcal.g⁻¹) in order to make participants eat to their satisfaction, without being concerned about food availability and also to avoid variations in the quantity of food offered to each individual, which could interfere in the food intake. Each individual ate alone with no time restriction. The quantity of pasta consumed was evaluated by the difference between the starting amount and the leftovers on the pan and the plate.

BIOCHEMICAL ANALYSES

Venous blood was drawn through an indwelling antecubital cannula into syringes. Blood was collected into tubes containing sodium fluoride and EDTA for the analysis of plasma glucose concentrations, in tubes containing clot activator and gel separator for insulin and TG, and in tubes containing EDTA and anti-DPP-IV protease inhibitor ($10 \mu\text{L}\cdot\text{mL}^{-1}$ of blood) for the GIP and GLP-1. All blood samples were kept in ice until centrifugation at 3500rpm for 15 minutes at 4°C , and serum and plasma samples were stored at -70°C until analysis.

The analyses were performed at 0 (fasting), 30, 60, 90, 120, 150, and 180 min (this latter period was considered as preprandial, because it occurred before the *ad libitum* meal). The times selected for analysis of the postprandial curve of GIP and GLP-1 were adapted from the methodology proposed by Verdich et al. (2001) (5), which were also similar to the times used in other studies that described/evaluated postprandial curves of these hormones (24,25).

Total GIP and GLP-1 were determined by the Luminex™ xMAP methodology, by means of the kit GIP and GLP-1-HGT-68k (Millipore®); sensitivities were 0.2 and $5.2 \text{ pg}\cdot\text{mL}^{-1}$, respectively, and the CV values were 3.7 and 8.7%, respectively. TG was quantified by the endpoint enzymatic method, by employing the kit Triglycerides Liquiform (Labtest®); sensitivity and CV were $0.99 \text{ mg}\cdot\text{dL}^{-1}$ and $\leq 5\%$, respectively.

Glucose was analyzed by the endpoint photometric method (Glucose PAP Liquiform), with the aid of the kit Glucose PAP Liquiform (Labtest®); the sensitivity and the coefficient of variation (CV) were $0.32 \text{ mg}\cdot\text{dL}^{-1}$ and 3.0% , respectively. Insulin was determined by the Luminex™ xMAP methodology, using the kit insulin-HGT-68K (Millipore®); sensitivity and CV were $1.1 \mu\text{U}\cdot\text{mL}^{-1}$ and 7.3% , respectively. TG was quantified by the endpoint enzymatic method, by employing the kit Triglycerides Liquiform (Labtest®); sensitivity and CV were $0.99 \text{ mg}\cdot\text{dL}^{-1}$ and $\leq 5\%$, respectively.

ASSESSMENT OF HUNGER, SATIETY, PREFERENCE AND PALATABILITY

Previously validated 100-mm visual analogue scales (VAS) were used to assess hunger ("How hungry do you feel now?") and satiety ("How full/satisfied do you feel now?") (26). The participants were asked to fill in VAS before breakfast (0 min) and 30, 60, 90, 120, 150 and 180 min after the end of this meal (the same times when biochemical analyses were accomplished).

Moreover, after meal, the participants were asked to fill in 100-mm VAS to evaluate preference ("How much do you like pasta bolognese?") and meal palatability ("How tasty are this pasta?").

SAMPLE CHARACTERIZATION

Anthropometric and body composition analysis

Body weight (kg) and height (m) were measured to calculate the body mass index (BMI, in $\text{kg}\cdot\text{m}^{-2}$). Body composition (fat mass and

fat free mass) was evaluated by bioelectric impedance analysis (Biodynamics 450 Bioimpedance Analyzer). These measures were taken at the beginning of the study, in a fasting state.

STATISTICAL ANALYSIS

The linear regression model with mixed effects (random and fixed effects) was employed to evaluate the differences in biochemical parameters and appetite between the groups at each time, as well as the difference between times within the same group. This methodology assumes that the residues have normal distribution, with mean 0 and constant variance σ^2 . When this assumption was not verified, the response variable was transformed with the aid of the software SAS®9.0 and PROC MIXED. The orthogonal contrasts post-test aided the comparisons. The comparisons for orthogonal contrasts do not include adjustments for multiple testing. To study the variation between the groups of variables measured along time, the trapezium rule was employed to estimate the area under the curve ($\text{AUC}_{\text{total}}$ and $\text{AUC}_{\text{incremental}}$) for each participant. To compare the variables of quantitative characterization (anthropometric and body composition data, *ad libitum* energy intake and biochemical and appetite variables in fasting) between the groups, non-parametric Mann-Whitney test was applied for independent samples. The correlations were determined by Spearman correlation coefficient. The level of significance was set at 5% ($p < 0.05$).

RESULTS

SUBJECT CHARACTERISTICS

There were no significant differences between the groups HTG and LTG for any anthropometric variables or fasting levels of biochemical parameters and appetite scores (Table I).

TRIGLYCERIDES (TG) AND POSTPRANDIAL INCRETIN RESPONSES (GIP AND GLP-1)

In HTG group ($n = 16$), the TG levels significant change from baseline at 60 min ($p < 0.01$) and remained at this level up to 180min. In contrast, for LTG group ($n = 17$), TG levels did not increase significantly as compared with basal levels at any of the evaluated times. The ΔTG (%) was higher in the HTG group compared to LTG group ($78.8 \pm 44.4\%$ vs. $16.7 \pm 18.4\%$, $p < 0.01$).

In the HTG group, the $\text{AUC}_{\text{incrementalGIP}}$ was significant lower when compared with LTG group ($2423 \pm 1979 \text{ pmol}\cdot\text{L}\cdot\text{min}^{-1}$ vs. $2809 \pm 1042 \text{ pmol}\cdot\text{L}\cdot\text{min}^{-1}$, respectively, $p = 0.03$) and $\text{AUC}_{\text{totalGIP}}$ also presented trend to be lower in this group ($p = 0.08$) (Table II). GIP was also significantly lower in HTG group at 150 min ($16.4 \pm 6.4 \text{ pmol}\cdot\text{L}^{-1}$ vs. $12.1 \pm 7.3 \text{ pmol}\cdot\text{L}^{-1}$, $p = 0.03$) and at 180 min ($13.8 \pm 4.7 \text{ pmol}\cdot\text{L}^{-1}$ vs. $9.2 \pm 6.3 \text{ pmol}\cdot\text{L}^{-1}$, $p < 0.01$) (Fig. 1).

Table I. Basal characteristics of the participants

		LTG group (n = 17)	HTG group (n = 16)	p-value
Anthropometric parameters and body composition	Age (years)	35.1 ± 5.6	35.6 ± 6.6	0.79
	Body weight (kg)	90.1 ± 12.9	91.0 ± 11.3	0.73
	BMI (kg.m ⁻²)	35.0 ± 3.0	35.0 ± 3.5	0.87
	Fat mass (%)	39.4 ± 3.0	39.9 ± 2.1	0.54
Biochemical evaluation at fasting	Triglycerides (mg.dL ⁻¹)	104.4 ± 27.7	97.4 ± 40.5	0.19
	Glucose (mg.dL ⁻¹)	82.1 ± 9.4	87.5 ± 12.4	0.13
	Insulin (μU.mL ⁻¹)	14.5 ± 8.3	16.7 ± 10.9	0.56
	GLP-1 (pmol.L ⁻¹)	4.7 ± 5.3	4.1 ± 6.3	0.63
	GIP (pmol.L ⁻¹)	3.6 ± 2.2	4.5 ± 3.8	0.29
Appetite scores at fasting	Hunger (mm)	41.7 ± 35.4	39.6 ± 33.0	0.81
	Satiety (mm)	23.5 ± 25.8	35.2 ± 35.0	0.27
<i>Ad libitum</i> food intake	<i>Ad libitum</i> food intake (kcal)	483 ± 211	580 ± 249	0.33
	Palatability (mm)	85.1 ± 24.4	85.4 ± 24.0	0.44
	Preference (mm)	82.3 ± 23.4	82.1 ± 25.2	0.90

Data are expressed as mean ± DP. LTG: low TG change group; HTG: high TG change group.

Table II. Postprandial responses of hormones and appetite scores in LTG and HTG groups

		LTG group (n = 17)	HTG group (n = 16)
GIP	AUC (180 min.pmol.L ⁻¹)	3775.6 (3229.5-4321.6)	3539.4 (2313.8-4764.9)*
	Incremental AUC (180 min.pmol.L ⁻¹)	2809.0 (2273.0-3345.1)	2423.1 (1368.9-3477.2)#
GLP-1	AUC (180 min.pmol.L ⁻¹)	1251.0 (675.5-1826.6)	1030.8 (315.6-1746.0)
Hunger	AUC (180 min.mm-1)	4849.4 (2798.5-6900.3)	5727.2 (3492.2-7962.2)
	Incremental AUC (180 min.mm-1)	-1846.8 (-3879.1-185.6)	-1362.2 (-4460.0-1735.6)
Satiety	AUC (180 min.mm-1)	11815.0 (9623.4-14006.0)	9745.3 (7898.7-11592.0)
	Incremental AUC (180 min.mm-1)	4816.8 (2770.4-6863.2)	4630.0 (2305.0-6955.6)

Data are expressed as mean and 95% CI. LTG: low TG change group; HTG: high TG change group. *p = 0.08; #p = 0.02.

Because of the presence of some undetectable and negative values in the postprandial period, it was not possible to calculate the AUC_{incrementalGLP-1}.

The AUC_{totalGLP-1} were similar between groups (Table II). There were no between-group differences for the GLP-1 at each time point (Fig. 1).

HUNGER, SATIETY, AND *AD LIBITUM* FOOD INTAKE

Satiety was significantly lower in HTG group at 120 min (46.4 ± 32.3 mm vs. 67.0 ± 25.2 mm in LTG group, p = 0.03) and at 150 min (30.2 ± 24.4 mm vs. 62.3 ± 26.0 mm in LTG group, p < 0.01). This same trend was noted at 180 min (27.6 ± 29.9 mm

vs. 44.5 ± 27.6 mm in LTG group, p = 0.08). There were no between-group differences for hunger at each time point (Fig. 2).

The HTG group showed a higher preprandial hunger (at 180 min) compared to hunger in fasting (64.2 ± 29.4 mm vs. 41.7 ± 35.4 mm, respectively, p < 0.01), which did not occur in LTG group (50.8 ± 31.7 mm vs. 39.6 ± 33.0 mm, respectively, p = 0.22) (Fig. 2).

Despite these findings, *ad libitum* energy intake, palatability, and preference were similar in both groups (Table I). However, it is noteworthy that HTG group presented 20% higher energy intake compared to LTG group, which corresponded to +97 kcal during this meal.




Figure 1.

Postprandial GIP and GLP-1 response along time in LTH and HTG groups (*significant difference between the groups).




Figure 2.

Postprandial hunger and satiety response along time in LTG and HTG groups (*significant difference between the groups).

TRIGLYCERIDES, INCRETIN RESPONSES AND APPETITE REGULATION

A positive correlation between preprandial TG levels and AUCTG with *ad libitum* food intake was found in the total sample ($r = 0,40$, $p = 0,03$ and $r = 0,38$, $p = 0,03$, respectively). Also for the total sample, an inverse correlation between preprandial TG levels and satiety (in the same period) was found ($r = -0,37$, $p = 0,04$). Only in LTG group, a positive correlation between GIP and GLP-1 (in fasting) with satiety ($r = 0.47$, $p = 0.05$ and $r = 0.70$, $p = 0.01$, respectively); and an inverse correlation between *ad libitum* food intake and $AUC_{totalGLP-1}$ ($r = -0.69$, $p = 0.01$) were observed.

DISCUSSION

The findings of this study pointed out that women with larger increase in circulating TG levels after a high-fat meal intake

exhibited some differences in incretin and appetite profile, that suggests attenuated postprandial GIP and satiety responses. We also found that preprandial TG levels and AUCTG levels correlated positively with *ad libitum* food intake, which indicates that TG somehow participated in appetite regulation.

Karatayev et al. (2009) (27) confirm the importance of post-prandial TG levels as a predictor of meal size in animals. However, the possibility that TG levels after a high-fat meal are causally related to subsequent hyperphagia still require further elucidation. Evidences suggests that circulating TG act physiologically on brain mechanisms, through orexigenic peptides, to stimulate feeding and, in particular, to mediate high-fat-induced hyperphagia (17,27,28). In fact, a lower secretion of GIP, which is a hormone with possible actions in the food intake regulation, were observed in the HTG group. Moreover, higher TG levels after a meal could be related to limited TG metabolism by the organism, which would stimulate food intake (29). This might point to difficult energy storage in the adipocytes, which could trigger

food intake as an attempt to revert the situation, since the human homeostatic system aims to maintain body storage (1,30).

However, despite these differences for the incretin between HTG and LTG groups, there was no impact on *ad libitum* energy intake. Some studies that aimed to assess GIP function in appetite and food intake using exogenous infusion of different rates (from 0.8 to 5.0 pmol.kg.min⁻¹) and distinct evaluation times did not find that GIP levels affected hunger, satiety, or prospective food intake (9,10). In contrast, Verdich et al. (2001) (5) showed an inverse correlation between the AUC_{IncrementalGIP} and *ad libitum* food intake, and our study also found a positive correlation between GIP and satiety (in fasting) in LTG group. Methodological differences, especially those related to the type of meal (quantity and quality) used to stimulate GIP secretion, and concomitant exogenous GIP infusion, may have been the reason for the diverse results. This is because several factors, such as chewing (31) and meal size and composition (25,32), can affect GIP levels, which are sensitive to abrupt and chronic alterations in the diet, especially those regarding the fat content (33).

Previous studies have demonstrated that exogenous infusion of GLP-1, in supraphysiological rates, reduces hunger and food intake (8-10). It is also known that GLP-1 reduces food intake in a dose-dependent way and the infusion rate was the only independent predictor of this reduction (3). In our work, it was observed that *ad libitum* food intake correlated negatively with AUC_{totalGLP-1} in at least one group (LTG group). However, most consistent relationship between GLP-1 with hunger and satiety upon physiologically stimulated secretion (secondary to food intake) were not found. Authors who used a methodological design similar to ours; i.e., GLP-1 secretion stimulated by food intake, did not find any GLP-1 effect on appetite or *ad libitum* food intake in eutrophic and men with obesity (5). Other studies that used infusions of exogenous GLP-1 at low rates (to reflect physiological postprandial concentrations) did also not detect any influence of GLP-1 on food intake (2,34). All these results suggest that, in physiological conditions, changes in GLP-1 along and after a meal do not significantly impact appetite regulation and subsequent energy intake in the short term, especially in individuals with obesity who seem to have an attenuated GLP-1 response during meals (5-7).

This lack of influence of GLP-1 in physiological conditions can be related to its short half-life, as well as GIP, which hinders the action of these hormones in appetite regulation. Both are, after its secretion, rapidly metabolized in their inactive forms by the enzyme DPP-IV, produced in high quantities by intestinal epithelial cells (33,35). Although providing an increased secretion in the postprandial period of around 5-10 times its baseline value, the biologically active quantity of these hormones in the blood stream is significantly smaller than the amount produced (36). Only about 10-15% of GLP-1 secreted reaches peripheral tissues and pancreatic β cells (35). It is important to consider the larger activity of DPP-IV verified in obesity; this degrades GLP-1 more precociously, thereby limiting its appetite-regulating actions in this condition (6,7).

Moreover, high-fat diets modify the intestine-brain axis communication, reduce the basal levels of GLP-1 and also reduce the

activation of the GLP-1 receptor, attenuating its posterior satiety signaling (37-39). Besides that, lipotoxicity (which is associated with high-fat diets intake) affects GLP-1 receptors expression and signaling (40,41). Therefore, individuals with obesity, who are chronically exposed to high-fat diets, undergo rapid GLP-1 inactivation and require larger GLP-1 receptor stimulus to produce its anorexigenic effects.

The sample size can be considered a limitation in this study since some analysis showed no conclusive results but rather borderline p-values. Due to the pulsatile incretin secretion, the AUC's analysis also can be a limitation to find more conclusive results. Furthermore, it is important to consider that other variables related to emotional and environmental factors that influence food intake are difficult to control. The simple fact of participating in a survey can interfere with food intake.

In conclusion, our findings showed that women with larger increments in TG levels after a high-fat meal presented differences in satiety scores and lower postprandial secretion of GIP. This indicated an impaired incretin and appetite profile in women with this metabolic profile, however with no impact on *ad libitum* food intake in short term.

REFERENCES

- Harrold JA, Doyey TM, Blundell JE, Halford JCG. CNS regulation of appetite. *Neuropharmacology* 2012;63(1):3-17.
- Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. *International Journal of Obesity* 2001;25(6):781-92.
- Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on *ad libitum* energy intake in humans. *Journal of Clinical Endocrinology & Metabolism* 2001;86(9):4382-9.
- Schirra J, Goke B. The physiological role of GLP-1 in human: Incretin, ileal brake or more? *Regulatory Peptides* 2005;128(2):109-15.
- Verdich C, Toubro S, Buemann B, Madsen JL, Holst JJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. *International Journal of Obesity* 2001;25(8):1206-14.
- Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. *Hormone and Metabolic Research* 2004;36(2):111-5.
- Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. *Journal of Clinical Endocrinology & Metabolism* 2010;95(2):872-8.
- Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. *International Journal of Obesity* 1999;23(3):304-11.
- Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? *Journal of Clinical Endocrinology & Metabolism* 2010;95(5):2367-75.
- Edholm T, Degerblad M, Gryback P, Hilsted L, Holst JJ, Jacobsson H, et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. *Neurogastroenterology and Motility* 2010;22(11):1191-200.
- Raben A, Andersen HB, Christensen NJ, Madsen J, Holst JJ, Astrup A. Evidence for an abnormal postprandial response to a high-fat meal in women predisposed to obesity. *American Journal of Physiology-Endocrinology and Metabolism* 1994;267(4):E549-E59.

12. Raben A, Tagliabue A, Christensen NJ, Madsen J, Holst JJ, Astrup A. Resistant starch - the effect on postprandial glycemia, hormonal response, and satiety. *American Journal of Clinical Nutrition* 1994;60(4):544-51.
13. Raben A, Andersen K, Karberg MA, Holst JJ, Astrup A. Acetylation of or beta-cyclodextrin addition to potato starch: Beneficial effect on glucose metabolism and appetite sensations. *American Journal of Clinical Nutrition* 1997;66(2):304-14.
14. Daousi C, Wilding JPH, Aditya S, Durham BH, Cleator J, Pinkney JH, et al. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. *Clinical Endocrinology* 2009;195-201.
15. Stock S, Leichner P, Wong ACK, Ghatei MA, Kieffer TJ, Bloom SR, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. *Journal of Clinical Endocrinology & Metabolism* 2005;90(4):2161-8.
16. Chang GQ, Karatayev O, Davydova Z, Leibowitz SF. Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. *Endocrinology* 2004;145(8):3904-12.
17. Chang GQ, Karatayev O, Ahsan R, Gaysinskaya V, Marwil Z, Leibowitz SF. Dietary fat stimulates endogenous enkephalin and dynorphin in the paraventricular nucleus: role of circulating triglycerides. *American Journal of Physiology-Endocrinology and Metabolism* 2007;292(2):E561-E70.
18. Leibowitz SF, Dourmashkin JT, Chang GQ, Hill JO, Gayles EC, Fried SK, et al. Acute high-fat diet paradigms link galanin to triglycerides and their transport and metabolism in muscle. *Brain Research* 2004;1008(2):168-78.
19. Gaysinskaya VA, Karatayev O, Chang GQ, Leibowitz SF. Increased caloric intake after a high-fat preload: Relation to circulating triglycerides and orexigenic peptides. *Physiology & Behavior* 2007;91(1):142-53.
20. Giacco R, Clemente G, Busiello L, Lasorella G, Riveccio AM, Rivellese AA, et al. Insulin sensitivity is increased and fat oxidation after a high-fat meal is reduced in normal-weight healthy men with strong familial predisposition to overweight. *International Journal of Obesity* 2003;27(7):790-6.
21. Casas-Agustench P, Lopez-Uriarte P, Bullo M, Ros E, Gomez-Flores A, Salas-Salvado J. Acute effects of three high-fat meals with different fat saturations on energy expenditure, substrate oxidation and satiety. *Clinical Nutrition* 2009;28(1):39-45.
22. Phillips LK, Prins JB. Update on incretin hormones. *Annals of the New York Academy of Sciences* 2012;1-20.
23. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007;132(6):2131-57.
24. Adam TCM, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. *British Journal of Nutrition* 2005;93(6):845-51.
25. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism* 2003;88(6):2706-13.
26. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. *International Journal of Obesity* 2000;24(1):38-48.
27. Karatayev O, Gaysinskaya V, Chang GQ, Leibowitz SF. Circulating triglycerides after a high-fat meal: predictor of increased caloric intake, orexigenic peptide expression, and dietary obesity. *Brain Res* 2009;1298:111-22.
28. Chang G-Q, Gaysinskaya V, Karatayev O, Leibowitz SF. Maternal High-fat diet and fetal programming: Increased proliferation of hypothalamic peptide-producing neurons that increase risk for overeating and obesity. *Journal of Neuroscience* 2008;28(46):12107-19.
29. Friedman MI, Harris RB, Ji H, Ramirez I, Tordoff MG. Fatty acid oxidation affects food intake by altering hepatic energy status. *American Journal of Physiology-Regulatory Integrative and Comparative Physiology* 1999;276(4):R1046-R53.
30. Wilding JPH. Neuropeptides and appetite control. *Diabetic Medicine* 2002;19(8):619-27.
31. Zhu Y, Hsu W, Hollis J. Increasing the number of masticatory cycles is associated with reduced appetite and altered postprandial plasma concentrations of gut hormones, insulin and glucose. *British Journal of Nutrition* 2013;384-90.
32. Yip RGC, Wolfe MM. GIP biology and fat metabolism. *Life Sciences* 2002;66(2):91-103.
33. Karras S, Goulis DG, Mintziori G, Katsiki N, Tzotzas T. The effects of incretins on energy homeostasis: Physiology and implications for the treatment of type 2 diabetes mellitus and obesity. *Current Vascular Pharmacology* 2012;10(6):781-91.
34. Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, et al. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. *British Journal of Nutrition* 1999;81(4):273-9.
35. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. *Endocrinology* 1999;140(11):5356-63.
36. Burcelin R. The incretins: a link between nutrients and well-being. *British Journal of Nutrition* 2005;93(Suppl 1):S147-S156.
37. Mul J, Begg D, Barrera J, Li B, Matter E, D'Alessio D, et al. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. *Am J Physiol Regul Integr Comp Physiol* 2013.
38. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. *Diabetes* 2003;52(2):252-9.
39. Williams DL, Hyvarinen N, Lilly N, Kay K, Dossat A, Parise E, et al. Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation. *Physiology & Behavior* 2011;103(5):557-64.
40. Poutout V. Lipotoxicity impairs incretin signalling. *Diabetologia* 2013;56(2):231-3.
41. Kang ZF, Deng Y, Zhou Y, Fan RR, Chan JCN, Laybutt DR, et al. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. *Diabetologia* 2013;56(2):423-33.